Alps Advisors Inc Biomarin Pharmaceutical Inc Transaction History

Alps Advisors Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $358,772 - $447,692	-4,830 Closed	0 $0
Q4 2021 Feb 09, 2022	BUY	$71.72 - $91.47 $4,159 - $5,305	58 Added 1.22%	4,830 $427,000
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $356,802 - $407,862	4,772 New	4,772 $369,000
Q3 2020 Nov 04, 2020	SELL	$71.87 - $131.03 $188,155 - $343,036	-2,618 Closed	0 $0
Q2 2020 Aug 05, 2020	SELL	$79.55 - $124.22 $22,989 - $35,899	-289 Reduced 9.94%	2,618 $323,000
Q1 2020 May 06, 2020	BUY	$71.37 - $96.85 $207,472 - $281,542	2,907 New	2,907 $246,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.